A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
Status:
Completed
Trial end date:
2015-12-15
Target enrollment:
Participant gender:
Summary
Essential thrombocythaemia is a disorder of bone marrow, which causes too many platelets to
be produced. Platelets are small cells carried around in the blood, which help form blood
clots. When patients have too many platelets, there is a risk of blood clots forming
unnecessarily and excessive bleeding. The aim of this study is to gain additional information
on the safety profile of Anagrelide (Xagrid(r)) and Hydroxyurea (also known as
hydroxycarbamide).